Upcoming Allied Market Research
Her2-positive Breast Cancer Market

HER2-Positive Breast Cancer Market

Size, Share, Competitive Landscape and Trend Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy Immunotherapy, Others), by Route of Administration (Oral, Parenteral, Others), by End User (Hospitals, Homecare, Specialty Clinics, Others) and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A15411
Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.


Human epidermal growth factor receptor 2 (HER2) is a gene that is linked to breast cancer development. Genes contain the recipes for numerous proteins required by a cell to remain healthy and function normally. This protein stimulates cancer cell proliferation. Cancer cells in around one out of every five breast tumors have extra copies of the gene that produces the HER2 protein. Breast cancers that are HER2-positive are more aggressive than other kinds of breast cancer. Although anticancer medications do not directly target the HER2 protein, certain regular chemotherapy treatments can be useful in treating HER2-positive breast tumors. Experts advise testing for the presence of HER2 in all invasive breast cancers since the results have a substantial impact on treatment recommendations and decisions. Except as part of a clinical trial, HER2 testing is not typically performed for ductal carcinoma in situ. When breast cancer recurs or expands, the cancer cells should be retested for HER2 and hormone receptor status, as these can alter after the original diagnosis.

COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the rise in the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HER2-positive breast cancer market. 

Top Impacting Factors:

  • Factors that drive the growth of the HER2-positive breast cancer market include the increase in HER2-positive breast cancer cases globally, which is expected to affect the demand for innovative medications for HER2-positive breast cancer therapy. 
  • Furthermore, strong immunotherapy adoption and favorable reimbursement are viewed as good indicators for the growth of the HER2-positive breast cancer market.
  • The rise in awareness of HER2-positive breast cancer, as well as the increase in healthcare spending globally, is expected to drive the market expansion.
  • Major firms are participating in the development of medicines for HER2-positive breast cancer and the introduction of new medications are anticipated to have a substantial impact on the HER2-positive breast cancer market.
  • A surge in R&D activities by leading companies to introduce an approved and effective treatment for HER2-positive breast cancer is expected to act as a market driver.
  • However, the market for HER2-positive breast cancer is expected to be severely hampered by high treatment costs combined with the discontinuation of late-stage clinical trials.

Market Trends:

New Product Launches to Flourish HER2-Positive Breast Cancer Market

In May 2019, the Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have the residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Key Benefits of Report:

  • This study presents the analytical depiction of the HER2-positive breast cancer along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the HER2-positive breast cancer market share.
  • The current market is quantitatively analyzed to highlight the HER2-positive breast cancer market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the HER2-positive breast cancer market.
  • The report provides a detailed HER2-positive breast cancer market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the HER2-Positive Breast Cancer Market Report:

  • Who are the leading market players active in the HER2-positive breast cancer market?
  • What current trends will influence the HER2-positive breast cancer market in the next few years?
  • What are the driving factors, restraints, and opportunities in the HER2-positive breast cancer market?
  • What future projections would help in taking further strategic steps?
  • What is HER2-positive breast cancer?
  • What is HER2-positive breast cancer market prediction for the future?
  • Who are the leading global players in the HER2-positive breast cancer market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the HER2-positive breast cancer market report?

HER2-Positive Breast Cancer Market Report Highlights

Aspects Details
By Treatment Type
  • Chemotherapy
  • Targeted Therapy Immunotherapy
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players F. Hoffmann-La Roche Ltd., AstraZeneca, Merck & Co., Inc., Fresenius Kabi AG, Baxter, Eli Lilly and Company, Bayer AG, Pfizer Inc., GlaxoSmithKline plc., Teva Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Mylan N.V., Novartis AG

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Purchase Options

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
Related Tags

Purchase Full Report of
Her2-positive Breast Cancer Market

Start reading.
This Report and over 71,233+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save the time of readers